Drug Profile
Research programme: gene therapies - Genetix Pharmaceuticals
Alternative Names: LentiDL™; LentiFVIII™; LentiNeur™; LentiRA™; LentiVue™Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Genetix Pharmaceuticals
- Developer bluebird bio; Brigham and Womens Hospital; Columbia University; Harvard University; INSERM
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia A; Hypercholesterolaemia; Macular degeneration; Neurological disorders; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypercholesterolaemia in France (Intrahepatic)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Macular-degeneration in USA (Ophthalmic)